Sundar S, Moorleedhur-Singh G S, Dube B, Singh V P, Kumar K
Department of Medicine, Institute of Medical Sciences, Banaras Hindu University Varanasi, India.
J Assoc Physicians India. 1993 Jan;41(1):23-5.
Danazol, 10 mg/kg/day (maximum 600 mg/day) was given in two divided doses for 14 days in 30 patients with haemophilia-A. Rise in factor-VIII level was observed in all the patients after one week of danazol therapy, irrespective of initial factor-VIII Levels. In haemophiliacs with less than 1% factor VIII level, rise was maximum (3-6 folds); mean factor-VIII level at 7th and 14th day of danazol therapy was 2.3 +/- 0.6% and 4.8 +/- 1.1%, respectively. Only marginal increase in factor-VIII was noted in haemophiliacs with initial factor-VII levels more than 3%. The raised level of factor-VIII persisted after stopping the therapy during the observation period of 2 more weeks, irrespective of initial levels. No adverse effect was observed during or after.
对30例甲型血友病患者给予达那唑,剂量为10毫克/千克/天(最大剂量600毫克/天),分两次给药,共14天。达那唑治疗一周后,所有患者的凝血因子VIII水平均有升高,与初始凝血因子VIII水平无关。在凝血因子VIII水平低于1%的血友病患者中,升高幅度最大(3至6倍);达那唑治疗第7天和第14天的平均凝血因子VIII水平分别为2.3±0.6%和4.8±1.1%。初始凝血因子VIII水平超过3%的血友病患者,凝血因子VIII仅有轻微升高。在停药后的另外2周观察期内,凝血因子VIII升高水平持续存在,与初始水平无关。在此期间及之后均未观察到不良反应。